Bone Biologics 

$1.18
0
-$0.01-0.84% Thursday 07:25

Statistics

Day High
1.19
Day Low
1.09
52W High
-
52W Low
-
Volume
5,168
Avg. Volume
-
Mkt Cap
2.12M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

3JunExpected
Q3 2025
Q4 2025
Next
-0.58
-0.5
-0.42
-0.34
Expected EPS
-0.54
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-14.65MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BBLG.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Stryker
SYK
Mkt Cap136.19B
Stryker Corporation is a leading medical technology company that offers a range of orthopedic products, competing directly with Bone Biologics in the bone repair and regeneration market.
Zimmer Biomet
ZBH
Mkt Cap19.92B
Zimmer Biomet Holdings, Inc. specializes in musculoskeletal healthcare, offering products that compete in the orthopedic sector, similar to Bone Biologics' offerings.
Medtronic
MDT
Mkt Cap116.33B
Medtronic plc provides medical technologies, services, and solutions, including bone healing and regeneration products, making it a competitor in the same space as Bone Biologics.
Boston Scientific
BSX
Mkt Cap149.24B
Boston Scientific Corporation offers products in various medical fields, including orthopedic surgery, competing with Bone Biologics in areas like bone growth and repair.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson, through its subsidiary DePuy Synthes, offers a wide range of orthopedic products, directly competing with Bone Biologics in the field of bone health and regeneration.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences, Inc., while primarily known for its biopharmaceutical products, has ventured into cell therapy, which could potentially compete with Bone Biologics' regenerative medicine approaches.
Pfizer
PFE
Mkt Cap140.15B
Pfizer Inc., with its broad range of healthcare products, has the potential to compete in the orthopedic and regenerative medicine space, overlapping with Bone Biologics' market.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie Inc. engages in the discovery, development, manufacture, and sale of a broad line of pharmaceuticals, including treatments that could compete with Bone Biologics in bone health and regeneration.
AMGEN
AMGN
Mkt Cap160.66B
Amgen Inc. focuses on human therapeutics, including osteoporosis treatment and bone health products, making it a competitor in the bone regeneration market alongside Bone Biologics.

About

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. It is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. The company's platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. The company was founded in 2004 and is headquartered in Burlington, Massachusetts.
Show more...
CEO
ISIN
US0980706008

Listings

0 Comments

Share your thoughts

FAQ

What is Bone Biologics stock price today?
The current price of BBLG.BOATS is $1.18 USD — it has decreased by -0.84% in the past 24 hours. Watch Bone Biologics stock price performance more closely on the chart.
What is Bone Biologics stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Bone Biologics stocks are traded under the ticker BBLG.BOATS.
What is Bone Biologics market cap?
Today Bone Biologics has the market capitalization of 2.12M
When is the next Bone Biologics earnings date?
Bone Biologics is going to release the next earnings report on June 03, 2026.
What were Bone Biologics earnings last quarter?
BBLG.BOATS earnings for the last quarter are -0.58 USD per share, whereas the estimation was -0.34 USD resulting in a -70.59% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Bone Biologics revenue for the last year?
Bone Biologics revenue for the last year amounts to 0 USD.
What is Bone Biologics net income for the last year?
BBLG.BOATS net income for the last year is -14.65M USD.
When did Bone Biologics complete a stock split?
Bone Biologics has not had any recent stock splits.